Clinical-stage pharma stock Theralase Technologies (TSXV:TLT) announced a significant breakthrough in the treatment of Herpes ...

University of Manitoba independent research verifies that RuvidarTM is more effective than acyclovir in the inactivation of Herpes Simplex Viruses post infection. TORONTO, ON / ACCESS Newswire / ...

University of Manitoba independent research verifies that RuvidarTM is more effective than acyclovir in the inactivation of Herpes Simplex Viruses post infection. TORONTO, ON / ACCESS Newswire / Febru ...

Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant of inducement equity awards to ...

Two sexually transmitted infections are spreading faster than ever. Our expert guide tells you everything you need to know, ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...